U.S. markets open in 7 hours 14 minutes
  • S&P Futures

    3,843.25
    +34.00 (+0.89%)
     
  • Dow Futures

    31,152.00
    +240.00 (+0.78%)
     
  • Nasdaq Futures

    13,079.00
    +168.00 (+1.30%)
     
  • Russell 2000 Futures

    2,236.30
    +37.10 (+1.69%)
     
  • Crude Oil

    62.69
    +1.19 (+1.93%)
     
  • Gold

    1,752.20
    +23.40 (+1.35%)
     
  • Silver

    27.06
    +0.61 (+2.33%)
     
  • EUR/USD

    1.2099
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3991
    +0.0069 (+0.50%)
     
  • USD/JPY

    106.5860
    +0.0840 (+0.08%)
     
  • BTC-USD

    46,150.11
    +1,945.71 (+4.40%)
     
  • CMC Crypto 200

    922.10
    -11.04 (-1.18%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

AstraZeneca working on vaccine with Oxford to target new variant, CEO says -La Repubblica

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Jan 26 (Reuters) - AstraZeneca Chief Executive Pascal Soriot said on Tuesday that the British drugmaker is working with Oxford University on a vaccine that will target the South African variant of COVID-19.

"Having said that, we're also working on a vaccine with Oxford University that will target the variant," Soriot told Italian daily La Repubblica in an interview https://bit.ly/2KWidAc published late on Tuesday.

(Reporting by Kanishka Singh in Bengaluru; Editing by Leslie Adler)